Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2022.0309
FOCUS ARTICLE
|
Pioneering genomic technologies driving transformative cancer research. |
Prof. Andreas Sendler, MD, PhD.
|
|
Abstract
The advent and refinement of next generation sequencing (NGS) CRISPR–Cas9 and regulatory genomic network mapping technologies have revolutionized biomedical cancer research. These advances provide promises to overcome current unmet challenges. First, to develop robust biomarkers for tailored treatment in individual patients. Second, to dramatically expand the catalogues of cancer genes and actionable mutations. These advances enhance the potential to improve oncological outcomes.
(Citation: Gastric & Breast Cancer 2022; 17(1): 1-5)
|
|
You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|